Bevacizumab誘導性グリオーマ浸潤に対してintegrin阻害剤が浸潤性変化を抑制する by Ishida, Joji
1 
 
Integrin inhibitor suppresses bevacizumab-induced glioma invasion 
 
Joji Ishida, Manabu Onishi, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Kentaro Fujii, 
Yosuke Shimazu, Tetsuo Oka, Isao Date  
 
Joji Ishida, Department of Neurological Surgery, Okayama University Graduate School 
of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2-5-1 
Shikata-Cho, Kita-ku Okayama 700-8558, JAPAN 
 
Manabu Onishi, Department of Neurological Surgery, Okayama University Graduate 
School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2-5-1 
Shikata-Cho, Kita-ku Okayama 700-8558, JAPAN 
 
Kazuhiko Kurozumi, Department of Neurological Surgery, Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 
2-5-1 Shikata-Cho, Kita-ku Okayama 700-8558, JAPAN 
 
Tomotsugu Ichikawa, Department of Neurological Surgery, Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 
2-5-1 Shikata-Cho, Kita-ku Okayama 700-8558, JAPAN 
 
Kentaro Fujii, Department of Neurological Surgery, Okayama University Graduate 
School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2-5-1 
Shikata-Cho, Kita-ku Okayama 700-8558, JAPAN 
 
Yosuke Shimazu, Department of Neurological Surgery, Okayama University Graduate 
School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2-5-1 
Shikata-Cho, Kita-ku Okayama 700-8558, JAPAN 
 
Tetsuo Oka, Department of Neurological Surgery, Okayama University Graduate School 
of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2-5-1 
Shikata-Cho, Kita-ku Okayama 700-8558, JAPAN 
 
Isao Date, Department of Neurological Surgery, Okayama University Graduate School 
of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2-5-1 
Shikata-Cho, Kita-ku Okayama 700-8558, JAPAN 
2 
 
 
Corresponding Author: Kazuhiko Kurozumi M.D., Ph.D. 
Address: 2-5-1 Shikata-Cho, Kita-ku Okayama 700-8558, JAPAN,  
Phon: +81-86-235-7336, FAX: +81-86-227-0191 
E-mail: kkuro@md.okayama-u.ac.jp 
 
Running title: The treatment for bevacizumab-induced glioma invasion 
 
Keywords: glioma, invasion, bevacizumab, cilengitide, integrin. 
 
 
 
 
3 
 
Abstract 
Glioblastoma is known to secrete high levels of vascular endothelial growth factor 
(VEGF), and clinical studies with bevacizumab, a monoclonal antibody to VEGF, have 
demonstrated convincing therapeutic benefits. However, its induction of invasive 
proliferation has also been reported. We examined the effects of treatment with 
cilengitide, an integrin inhibitor, on bevacizumab-induced invasive changes in glioma. 
U87ΔEGFR orthotopic rat and mouse models were treated by cilengitide and/or 
bevacizumab intraperitoneally. We analyzed brain tumors histopathologically about the 
three following groups: untreated, treated with bevacizumab, and treated with a 
combination of bevacizumab and cilengitide. Next, the combination group was 
compared to the bevacizumab monotherapy group using microarray analysis of 
extracted RNA from U87ΔEGFR brain tumors. Bevacizumab treatment led to increased 
cell invasion in spite of decreased angiogenesis. In the combination group, the depth of 
tumor invasion was significantly less than with only bevacizumab. Pathway analysis 
using the microarray data demonstrated the inhibition of invasion-associated genes such 
as the integrin-mediated cell adhesion pathway in the combination group. This study 
showed that the combination of bevacizumab with cilengitide exerted its anti-invasive 
effect by suppressing the integrin-mediated cell adhesion pathway. The elucidation of 
this mechanism might contribute to the treatment of bevacizumab-refractory glioma. 
 
4 
 
Introduction 
Glioblastoma is one of the most frequent and aggressive intracranial neoplasms in 
humans and its prognosis remains poor despite the advancement of basic and clinical 
research. The median survival of patients diagnosed with glioblastoma is approximately 
12–14 months [1]. The typical features of malignant glioma include aggressive 
proliferation, a strong invasive capacity, and extensive angiogenesis. Recently, new 
therapeutic agents such as various molecular targeted drugs have been developed and 
clinical trials have been conducted.  
Glioblastoma cells are known to secrete high levels of vascular endothelial growth 
factor (VEGF), and clinical studies with the humanized monoclonal antibody 
bevacizumab, which targets the pro-angiogenic VEGF, have demonstrated significant 
therapeutic benefits in patients with recurrent glioblastoma [2-4]. Recently, the results 
of the positive phase III AVAglio and RTOG 0825 studies, which were presented at the 
49th Annual American Society of Clinical Oncology (ASCO) Meeting in 2013, showed 
that bevacizumab in combination with radiation and temozolomide chemotherapy 
reduced the risk of progression-free survival in patients with newly diagnosed 
glioblastoma; however, overall survival did not reach statistical significance. Although 
anti-VEGF therapies including bevacizumab have been shown to decrease vascular 
permeability rapidly, which manifests as a decrease in contrast on enhanced magnetic 
resonance imaging, they do not improve the long-term outcome of patients [5]. Piao et 
al. showed that anti-VEGF therapy induces a phenotypic shift toward a more invasive, 
aggressive, and treatment-resistant phenotype associated with mechanisms similar to the 
epithelial to mesenchymal transition [6].  
Integrins control the attachment of cells to the extracellular matrix (ECM) and 
participate in processes such as cell migration, differentiation, and survival during 
embryogenesis, angiogenesis, wound healing, and cellular defense against genotoxic 
assaults [7]. Several integrin-targeted drugs are in clinical trials as potential compounds 
for the treatment of cancer. Cilengitide (EMD121974), a cyclic 
arginine-glycine-aspartic (RGD) acid pentapeptide, is an αvβ3 and αvβ5 integrin 
antagonist that induces anoikis and apoptosis in human endothelial cells and brain 
tumor cells [8,9]. Cilengitide might inhibit adhesion to the ECM, thereby suppressing 
the invasion of glioma [10]. This agent is currently being assessed in phase III trials for 
glioblastoma patients and phase II trials for other types of cancers, with promising 
therapeutic outcomes reported to date [11].  
The purpose of this study was to investigate the phenotypic changes in radiographic 
tumor progression that have been observed in some patients receiving bevacizumab. We 
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found that anti-VEGF treatment led to perivascular and subpial tumor invasion. 
Moreover, we investigated the pathological and molecular changes of the 
anti-angiogenic and anti-invasive effects using combination therapy of bevacizumab 
and the integrin antagonist cilengitide. 
 
 
Materials and Methods 
Glioma cell line and drug 
The human glioma cell line U87ΔEGFR was seeded in tissue culture dishes (BD Falcon, 
Franklin Lakes, NJ, USA) and cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U penicillin, and 0.1 
mg/mL streptomycin. U87ΔEGFR cells were prepared and maintained as described 
previously [12]. Cilengitide (EMD121974) was generously provided by Merck KgaA 
(Darmstadt, Germany) and the Cancer Therapy Evaluation Program, National Cancer 
Institute, National Institutes of Health. Bevacizumab was provided by Genentech (San 
Francisco, CA, USA) /Roche (Basel, Swiss) /Chugai Pharmaceutical Co (Tokyo, Japan). 
 
Brain xenografts 
All experimental animals were housed and handled in accordance with the guidelines of 
the Animal Research Committee of Okayama University. Before implantation, 85–90% 
confluent U87ΔEGFR cells were trypsinized, rinsed with DMEM supplemented with 
10% FBS, and centrifuged at 100 × g for 5 min; the resulting pellet was resuspended in 
phosphate-buffered saline (PBS), and the cell concentration was adjusted to 1.0 × 10
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cells/μL. U87ΔEGFR cells (5 µL) were injected into athymic rats (F344/N-rnu/rnu; 
CLEA Japan, Inc., Tokyo, Japan) and U87ΔEGFR cells (2 µL) were injected into 
athymic mice (balb/c-nu/nu; CLEA Japan, Inc, Tokyo, Japan). The animals were 
anesthetized and placed in stereotactic frames (Narishige, Tokyo, Japan) with their 
skulls exposed. Tumor cells were injected with a Hamilton syringe (Hamilton, Reno, 
NV, USA) into the right frontal lobe (in the athymic rats: 4 mm lateral and 1 mm 
anterior to the bregma at a depth of 4 mm; in the athymic mice: 3 mm lateral and 1 mm 
anterior to the bregma at a depth of 3 mm) and the syringe was withdrawn slowly after 5 
min to prevent reflux. The skulls were then cleaned and the incision was sutured. PBS, 
bevacizumab (for the athymic mice and rats: 6 mg/kg), cilengitide (for the athymic mice 
and rats: 10 mg/kg), or a combination of bevacizumab and cilengitide of the same 
amount was administered 3 times/week intraperitoneally, starting on day 5 after tumor 
cell implantation. 
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Transmission electron microscopy 
Athymic rats harboring U87ΔEGFR brain tumors were sacrificed at 18 days after tumor 
implantation and 6 times administration of PBS, bevacizumab, cilengitide, or the 
combination of bevacizumab and cilengitide. The brains were removed and fixed 
immediately by perfusion of 2% glutaraldehyde. After fixation in 2% osmium tetroxide, 
the samples were dehydrated and embedded in Spurr’s resin. Thin sections poststained 
with salts of uranium and lead were cut to approximately 60 nm using an 
ultramicrotome (Leica EM UC6, Wetzlar, Germany). The samples were observed under 
a transmission electron microscopy (Hitachi H-7650 TEM, Tokyo, Japan).  
 
Histopathological analysis of glioma  
For histopathological analysis, athymic rats harboring U87ΔEGFR brain tumors were 
sacrificed at 18 days after tumor implantation. Athymic rats were anesthetized, 
euthanized by cardiac puncture, perfused with 100 mL PBS, and fixed with 50 mL 4% 
paraformaldehyde (PFA). The brains were removed and stored in 4% PFA for 12–24 h. 
Hematoxylin and eosin (HE) staining was performed as described previously [13]. For 
immunohistochemistry of PFA perfusion-fixed frozen sections, snap-frozen tissue 
samples were embedded in optimal cutting temperature compound for cryosectioning, 
and 16-μm thick sections were processed for indirect immunofluorescence. After 
blocking non-specific binding with 10% normal goat serum, the slides were incubated 
overnight at 4°C with primary antibodies, including those targeting rat endothelial cell 
antigen 1 (RECA-1) (1:20, mouse monoclonal; Abcam, Inc., Cambridge, UK), von 
Willebrand factor (1:250, rabbit polyclonal; Abcam, Inc., Cambridge, UK), integrin 
αvβ3 (1:100, mouse monoclonal; Abcam, Inc., Cambridge, UK), and integrin αvβ5 
(1:75, mouse monoclonal; Abcam, Inc., Cambridge, UK), after blocking with 10% 
normal goat serum. After three washes with PBS containing 0.01% Tween 20 for 5 min, 
the slides were incubated with Alexa Fluor
®
 594-conjugated and Alexa Fluor
®
 
488-conjugated secondary antibodies (Abcam, Inc., Cambridge, UK) and 
4',6-diamidino-2-phenylindole (DAPI) (1:500) (Invitrogen, Carlsbad, CA, USA) in PBS 
for 60 min. The slides were then washed in PBS and mounted. 
 
Microarray analysis  
Orthotopic U87ΔEGFR xenograft mouse models treated with bevacizumab or the 
combination of bevacizumab and cilengitide were sacrificed at 18 days after tumor 
implantation (n = 3 per treatment). Approximately 40 mg of brain tumor samples were 
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excised cleanly from each mouse and RNA was extracted using TRIzol (Life 
Technologies, Carlsbad, CA, USA) and an RNeasy Mini Kit (QIAGEN, Venlo, 
Netherlands). They were analyzed using a CodeLink™ Human Whole Genome 
Bioarray (Applied Microarrays, Inc., Tempe, AZ, USA). We entrusted the microarray 
analyses to Filgen, Inc. (Nagoya, Japan). Briefly, for each bioarray, 10 μg of 
biotin-labeled aRNA, which was prepared using a MessageAmp™ II-Biotin Enhanced 
Kit in a total volume of 25 µL, were added to 5 μL of 5× fragmentation buffer, which 
was then incubated at 94°C for 20 min. Thereafter, 10 μg fragmented cRNA, 78 μL 
hybridization buffer component A, and 130 μL hybridization buffer component B were 
added, and the final volume was brought up to 260 μL with water. The resultant 
hybridization reaction mixture was incubated at 90°C for 5 min, after which 250 μL 
were slowly injected into the input port of each array, and the ports were sealed with 
sealing strips. The bioarrays were incubated for 18 h at 37°C while shaking at 300 rpm. 
A consistent hybridization time was maintained for comparative experiments. Following 
the incubation, the bioarrays were washed with 0.75 TNT buffer (0.10 M Tris-HCl, pH 
7.6, 0.15 M NaCl, 0.05% Tween 20) and incubated at 46°C for 1 h. Each slot of the 
small reagent reservoir was then filled with 3.4 mL Cy5-streptavidin working solution, 
and the array was incubated at 25°C for 30 min. Thereafter, the bioarrays were washed 4 
times for 5 min each with 1 × TNT buffer at 25°C, rinsed twice in 0.1× SSC (Ambion, 
Austin, TX, USA)/0.05% Tween 20 for 30 s each, and immediately dried by 
centrifugation for 3 min at 25°C. Finally, the arrays were scanned using a 
GenePix4000B Array Scanner (Molecular Devices, Sunnyvale, CA, USA). A gene was 
defined as being upregulated when the combination therapy/bevacizumab monotherapy 
average intensity ratio was >2.0, and downregulated when the combination 
therapy/bevacizumab monotherapy ratio was <0.5. We performed pathway analysis on 
the genes with increased and decreased expression using Microarray Data Analysis Tool 
Ver3.2 (Filgen, Inc., Nagoya, Japan). The data were extracted using the following 
criteria: Z-score > 0 and P-value < 0.05. 
 
Quantitative reverse-transcription polymerase chain reaction (QRT-PCR) 
Total RNA was isolated from cultured U87ΔEGFR cells treated with cilengitide (1.0 
μM for 16 h) and untreated control U87ΔEGFR cells using an RNeasy® Mini Kit 
(QIAGEN, Hilden, Germany). In vivo, total RNA was extracted from the brain tumor 
tissue of mice that had been treated with PBS or cilengitide using the TRIzol reagent 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. RNA 
was reverse transcribed with oligo dT primers using the SuperScript III First-Strand 
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Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA) according to 
manufacturer’s instructions. Primers specific to each gene were designed using Primer 3 
Plus Software (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and 
synthesized by Invitrogen. The resulting cDNA was amplified by PCR using the 
gene-specific primers and the 7300 Real Time PCR system (Applied Biosystems, Foster 
City, CA, USA) and a QuantiTectTM SYBR® Green PCR Kit (QIAGEN, Hilden, 
Germany). A log-linear relationship between the amplification curve and quantity of 
cDNA in the range of 1–1000 copies was observed. The cycle number at the threshold 
was used as the threshold cycle (Ct). Changes in the expression of mRNA were detected 
from 2-ΔΔCt using the 7300 Real Time PCR System with Sequence Detection Software 
(version 1.4; Applied Biosystems, Foster City, CA, USA). The amount of cDNA in each 
sample was normalized to the crossing point of the housekeeping gene glyceraldehyde 
3-phosphate dehydrogenase (GAPDH). The following thermal cycling parameters were 
used: denaturation at 95°C for 10 min followed by 45 cycles at 94°C for 15 s, 55°C for 
30 s, and 72°C for 30 s. The relative upregulation of mRNA for each gene in the control 
was calculated using their respective crossing points with the following formula, as 
previously described [14]:  
F = 2
(TH − TG) − (OH − OG)
 where, F = fold difference, T = control, O = treated cell or 
tumor, H = housekeeping gene (GAPDH), and G = gene of interest. 
c-src tyrosine kinase primers: 
    CSK F (forward), 5′-GAATACCTGGAGGGCAACAA-3′  
CSK R (reverse), 5′-ATTCCGAAACTCCACACGTC-3′  
caveolin 3 primers: 
    CAV3 F (forward), 5′-TTTGCCAAGAGGCAGCTACT-3′  
    CAV3 R (reverse), 5′-ACCCTTTACTGGAGCCACCT-3′ 
GAPDH primers:  
GAPDH F (forward), 5′- GAGTCAACGGATTTGGTCGT-3′ 
GAPDH R (reverse), 5′-TTGATTTTGGAGGGATCTCG-3′ 
 
To assess the gene expression of caveolin 3 and c-src tyrosine kinase with 
QRT-PCR, athymic mice harboring U87ΔEGFR brain tumors were sacrificed at 18 days 
after tumor implantation. The tumor-bearing right hemispheres of the brains were 
excised and processed for RNA.  
 
Statistical analysis 
Student’s t test was used to test for statistical significance. Data are presented as the 
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mean ± standard error. P < 0.05 was considered statistically significant. All statistical 
analyses were performed with the use of SPSS statistical software (version 20; SPSS, 
Inc., Chicago, IL, USA). 
 
 
Results 
Anti-angiogenic effect of bevacizumab 
U87ΔEGFR orthotopic tumors proliferate with aggressive angiogenic growth (Figure 
1A). Treatment with bevacizumab reduced angiogenesis in U87ΔEGFR orthotopic 
tumor tissues in the rat with a regression of tumor size (Figure 1B). The density of 
tumor vessels was significantly decreased by bevacizumab (Figure 1C). The short 
diameter of tumor vessels tended to be larger, but there was no significant difference 
(Figure 1D). Quantitative assessment of tumor vascularity results in a remarkable 
regression of tumor vessels (Figure 1E).  
 
Microstructure of tumor vessels in the border area with bevacizumab treatment  
The structure of the blood-brain barrier of cerebral capillaries was composed of a single 
endothelial cell, juxtaposing membranes with a tight junction, pericytes attached to the 
abluminal surface of endothelial cells, a basal lamina surrounding these cells, and close 
contact with the plasma membranes of astrocyte end-feet [15]. We observed that there 
was no space between the basal lamina and astrocyte end-feet (AE) for capillaries in the 
contralateral normal brain (Figure 2A). The fuzzy basal lamina and loose ECM were 
observed at perivascular space in the center area of an untreated U87ΔEGFR tumor (see 
Supplementary Figure 1A). In the center area of a bevacizumab-treated U87ΔEGFR 
tumor, ECM was thickened and numerous collagen fibers were increased at perivascular 
space (see Supplementary Figure 1B). In contrast, there was a distance of more than 250 
nm between endothelial cells and tumor cells and there was also a fuzzy basal lamina 
near the border area of the tumor (Figure 2B). When treated with bevacizumab, the 
distance between the endothelial cells and tumor cells was reduced in conjunction with 
the normalization and orderliness of the basal lamina (Figure 2C, D).    
 
Anti-angiogenic therapy induced an invasive phenotype in the orthotopic glioma 
model 
The rat orthotopic glioma model implanted with U87ΔEGFR cells displayed angiogenic 
growth and well-deﬁned borders toward the brain tissue (Figure 3A). However, after 
anti-VEGF therapy with bevacizumab, we observed increased cell invasion and vascular 
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co-option (Figure 3B).  
 
Integrin αvβ3 and αvβ5 expression in glioma cell lines 
Using immunohistochemistry, we demonstrated that U87ΔEGFR cells expressed high 
levels of αvβ3 and αvβ5 integrin (Figure 4A, B). Furthermore, integrin αvβ3 and αvβ5 
was immunohistochemically expressed at tumor endothelial cells and surrounding 
tumor cells in the rat orthotopic glioma model with U87ΔEGFR cells (Figure 4C, D). 
Therefore, we examined the combined effect of the integrin inhibitor cilengitide and 
bevacizumab on glioma models in vivo. 
 
Effect of cilengitide on bevacizumab-induced invasion 
The rat orthotopic glioma model with U87ΔEGFR cells die at approximately 20 days 
after implantation. Tumors in the untreated group were strongly proliferative and 
expanded with well-deﬁned borders (Figure 5A). When treated with bevacizumab, the 
tumor surface became irregular, and strong invasiveness was induced in the U87ΔEGFR 
model (Figure 5B). Thus, when this model was treated with a combination of 
bevacizumab and cilengitide, the depth of tumor invasion was remarkably decreased 
(Figure 5C and D). These results demonstrated that cilengitide reduced 
bevacizumab-induced invasion. 
 
Effects on the structure of tumor vessels by combination treatment with bevacizumab 
and cilengitide 
We also focused on the effect of combination therapy with anti-VEGF and anti-integrin 
agents on tumor vessels. The vascularity of tumors treated with bevacizumab and 
cilengitide was strongly suppressed (Figure 6A). Similar to bevacizumab-treated tumors, 
cluttered and dense ECM around endotherial cells following combination therapy was 
observed by a transmission electron microscopy (see Supplementary Figure 1C). 
Notably, the tumor vessels around the area of the tumor border retained an orderly 
structured basal lamina (Figure 6B and C). Although the density of tumor vessels 
following combination therapy was inhibited to the same extent as with bevacizumab 
monotherapy (Figure 6D), the diameter of tumor vessels following combination therapy 
was significantly smaller than following bevacizumab monotherapy (Figure 6E).  
Additionally, vascularity of tumors following combination therapy was significantly less 
than that of bevacizumab-treated tumors (Figure 6F). 
 
Microarray analysis of the effect of combination treatment compared to bevacizumab 
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monotherapy on the U87ΔEGFR orthotopic mouse model  
To characterize the molecular mechanisms underlying the anti-invasive response to 
combination therapy, we analyzed the changes in gene expression of tumor tissues in 
the U87ΔEGFR orthotopic mouse model treated with bevacizumab and cilengitide 
combination therapy compared to bevacizumab monotherapy. We identified 947 
differentially expressed genes between bevacizumab-treated U87ΔEGFR glioma tissue 
and bevacizumab plus cilengitide-treated U87ΔEGFR glioma tissue, which consisted of 
486 upregulated genes and 461 downregulated genes (Figure 7A). Further, we 
characterized the functional significance of these dysregulated genes using pathway 
analysis. For the downregulated genes, the following three significantly enriched 
pathways were identified: integrin-mediated cell adhesion pathway, signaling of 
hepatocyte growth factor (HGF) receptor pathway, and GPCRs, class C metabotropic 
glutamate, pheromone pathway (Table 1). For the upregulated genes, the following 
three significantly enriched pathways were identified: inflammatory response pathway, 
serotonin receptor 2 and ELK-SRF-GATA4 signaling pathway, and serotonin receptor 
4-6-7 and NR3C signaling pathway (Table 2). 
 
Validation of the microarray results 
To confirm the reliability of the results from the microarray analysis, caveolin 3 and 
c-src tyrosine kinase, which were included in the integrin-mediated cell adhesion 
pathway and associated with tumor invasion, were verified by QRT-PCR analysis. The 
relative expression of caveolin 3 and c-src tyrosine kinase in the U87ΔEGFR mouse 
orthotopic model treated with cilengitide and bevacizumab was significantly reduced 
compared with bevacizumab monotherapy by 0.38-fold and 0.44-fold, respectively (p < 
0.05) (Figure 7B).  
 
 
Discussion 
Tumor angiogenesis in the glioma orthotopic models was decreased by treatment with 
bevacizumab. Conversely, bevacizumab treatment resulted in enhanced tumor invasion. 
In this study, we demonstrated that cilengitide, an inhibitor of these integrins, inhibited 
bevacizumab-induced glioma invasion in vivo. Microarray analysis of combination 
treatment compared to bevacizumab monotherapy on the U87ΔEGFR orthotopic mouse 
model showed that pathways such as the integrin-mediated cell adhesion pathway or 
signaling of HGF receptor pathway were associated with the anti-invasive mechanism 
of cilengitide. Moreover, we focused on the ultra-micro structure of tumor vessels. 
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Since a tight junction was maintained between the endothelial cells, disintegration of a 
basal lamina was considered to represent a broken blood-brain barrier. This observation 
revealed that bevacizumab increased perivascular ECM such as collagen fibers in the 
central area of the tumor and closed the normal blood-brain barrier with an orderly 
ECM wall in the border area of the tumor. Adding cilengitide further reduced the 
number of tumor vessels with a normalized blood-brain barrier at the border of the 
tumor.  
 The conditional approval of bevacizumab by the US Food and Drug 
Administration in 2009 for patients with recurrent glioblastoma was linked to future 
demonstrations of its efficacy in prospective trials of newly diagnosed patients. Two 
such trials were performed, largely in parallel—one by RTOG (RTOG-0825) and one 
by Roche (AVAGlio) [16]. At the 2013 ASCO meeting in Chicago, the results from 
both trials were shown to provide a uniform picture: progression-free survival was 
significantly prolonged, and quality of life was preserved in the AVAGlio trial, but not 
in RTOG-0825. Safety and tolerability were acceptable, but overall survival was not 
improved.  
Several reports mentioned that increased tumor invasiveness is a major refractory to 
the antiangiogenic therapy. de Groot et al. described 3 patients who, during 
bevacizumab therapy, developed infiltrative lesions visible by MRI and presented the 
data that pair imaging features seen on MRI with histopathologic findings [17]. Delay et 
al. revealed hyperinvasive phenotype, which was one of resistance patterns of 
glioblastoma after bevacizumab therapy, was upregulated with integrin signaling 
pathway including integrin α5 and fibronectin 1 [18]. Our results also showed 
bevacizumab treatment led to increased cell invasion in spite of decreased angiogenesis. 
Previous reports showed integrin αvβ3 and αvβ5 plays a central role in glioma 
invasion and inhibition of integrins decreased glioma cell motility in vitro [19,20]. We 
reported that cilengitide exerts its anti-tumor effects by inhibiting tumor angiogenesis 
and invasion or by inducing apoptosis-related pathways [9,13,21]. We recently 
established two novel invasive animal glioma models (J3T-1 and J3T-2) that reflect the 
invasive phenotype of human malignant gliomas [22]. These models were particularly 
beneficial to investigate the anti-invasive effects of cilengitide [13]. Currently, 
cilengitide is being assessed in phase II and phase III trials for patients with newly 
diagnosed glioblastoma [11,23]. Lombardi et al. recently reported two cases with 
bevacizumab-refractory high-grade glioma treated with cilengitide [24].  
Some recent reports proved that the inhibition of VEGF promoted glioma invasion 
through HGF-dependent MET phosphorylation in association with phenotypic changes 
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such as the epithelial to mesenchymal transition [25,26]. The present study 
demonstrated that an antagonist of αvβ3 and αvβ5 integrin prevented 
bevacizumab-induced invasion in orthotopic glioma models that expressed these 
integrins at high levels. In the microarray analysis, combination therapy had reduced 
expression of genes in the integrin-mediated cell adhesion pathway and signaling of 
HGF receptor pathway compared to bevacizumab monotherapy. These data may 
indicate the mechanisms underlying the anti-invasive effects of cilengitide on glioma.  
We showed that bevacizumab and cilengitide reduced tumor vascularity by 
changing the diameter and density of tumor vessels in the in vivo glioma models. Von 
Baumgarten et al. reported that bevacizumab decreased vascular density and normalized 
the vascular permeability of glioma [27]. Conversely, cilengitide was shown to shrink 
the diameter of tumor vessels in angiogenesis-dependent invasive glioma models [13]. 
Moreover, we investigated the ultra-micro structure of tumor vessels and proved that 
bevacizumab reduced the distance between endothelial cells and tumor cells with a 
broken basal lamina at the blood-brain barrier in the border of the tumor. We also 
focused the ECM of gliomas which is considered to play as a critical regulator of 
angiogenesis and invasiveness [28]. In the center area of U87ΔEGFR tumors following 
bevacizumab treatment and combination therapy of bevacizumab and cilengitide, ECMs 
were thickened remarlably at perivascular space with respectively different 
characteristics. Fibronectin, vitronectin, laminin, tenascin, and diﬀerent types of 
collagen promote invasion of glioma [29,30], in contrast, glycosylated chondroitin 
sulfate proteoglycans consisting ECMs inhibit invasion in glioma [31]. These different 
mechanisms might be necessary for the regulation of tumor angiogenesis and invasion; 
however, the detailed mechanisms have not been elucidated and they need to be 
clarified in the future. 
 
 
Conclusions 
This study showed that anti-VEGF therapy induced glioma invasion despite its intense 
anti-angiogenic effect; however, the combination of bevacizumab with the αvβ3 and 
αvβ5 integrin inhibitor cilengitide exerted a significant anti-invasive effect. We revealed 
that combination therapy suppressed the integrin-mediated cell adhesion pathway as an 
underlying mechanism of its anti-invasive effect.  
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Figure legends 
 
Figure 1 
Anti-angiogenic effect of bevacizumab 
(A) Tumor vessels identified with RECA-1. Untreated U87ΔEGFR orthotopic tumor 
was observed with angiogenic growth. (B) The reduction of tumor vessels with 
bevacizumab therapy. Quantitative assessment of tumor vessels between no treatment 
and bevacizumab therapy was shown in following graphs. (C) Bevacizumab decreased 
vessel density of tumors significantly. (D) There was no significant difference about 
vessel short diameter of tumors. (E) Intensity of vessel area stained with RECA-1 was 
significantly reduced in bevacizumab-treated tumors. Bar: 100 μm. *p < 0.01. HPF, high 
power field.  
 
Figure 2 
Microstructure of tumor vessels in the border area with bevacizumab treatment  
(A) Contralateral normal brain. There was no space between the basal lamina and 
astrocyte end-feet (AE) (black arrowheads). (B) There was a distance of more than 250 
nm around the tumor microvessels; the fuzzy basal lamina and tumor cytoplasm (white 
arrowheads and double-headed black arrows) were separated in the border area of 
untreated U87ΔEGFR tumors. Conversely, a tight junction (white arrows) was 
maintained between the endothelial cells. (C) There was less space between the basal 
lamina and AE in the border area of bevacizumab-treated tumors compared to untreated 
tumors. (D) The distance between the endothelial cells and tumor was significantly 
narrowed in bevacizumab-treated tumors (Bev) compared to PBS-treated tumors (PBS). 
L: Lumen of vessels, Bar: 1 μm. *p < 0.01.  
 
Figure 3 
Anti-angiogenic therapy induces invasion in the orthotopic glioma model 
(A) Well-deﬁned borders toward the brain tissue in an untreated U87ΔEGFR orthotopic 
rat tumor. (B) Tumor cell invasion with vascular co-option in a bevacizumab-treated 
tumor. Bar: 100 μm. 
 
Figure 4 
Expression of integrin αvβ3 and αvβ5 in the glioma cell line 
U87ΔEGFR cells expressed (A) αvβ3 and (B) αvβ5 integrin at a high level, especially 
αvβ3, in immunocytochemistry. (C) Integrin αvβ3 and (D) αvβ5 were expressed at a 
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high level in tumor vessels stained with von Willbrand factor and surrounding tumor 
cells in U87ΔEGFR rat orthotopic tumors. Bar: 50 μm. 
  
Figure 5 
The effect of cilengitide on bevacizumab-induced invasion 
(A) HE staining of an untreated U87ΔEGFR rat orthotopic tumor demonstrated the 
expansion of the tumor with well-deﬁned borders. (B) Following treatment with 
bevacizumab (Bev), the tumor border was irregular with tumor invasion. (C) Tumor 
invasiveness was reduced at the tumor border following combination therapy with 
bevacizumab and cilengitide (Bev+Cile) compared to bevacizumab monotherapy. (D) 
The depth of tumor invasion following treatment with bevacizumab and cilengitide was 
remarkably decreased compared to bevacizumab monotherapy. Bar: 200 μm. *p < 0.01.  
 
Figure 6 
Effects of combination treatment with bevacizumab and cilengitide on tumor vessel 
structure 
(A) The tumor vessels treated with bevacizumab and cilengitide were inhibited more 
strongly than with bevacizumab treatment. Bar: 100 μm. (B) (C) Tumor vessels around 
the tumor border area retained an orderly structured basal lamina. L: Lumen of vessels, 
Bar: 5 μm. (D) The tumor vessel density following combination therapy (Bev+Cile) was 
inhibited to the same extent as with bevacizumab treatment (Bev), and the tumor vessel 
diameter was significantly smaller with combination therapy than with bevacizumab 
treatment (E). (F) Intensity of RECA-1 following combination therapy (Bev+Cile) was 
significantly less than that of bevacizumab-treated tumors. *p < 0.05. HPF, high power 
field.  
 
Figure 7 
Microarray analysis of the effect of combination treatment compared to bevacizumab 
monotherapy 
(A) There were 947 differentially expressed genes between the bevacizumab 
monotherapy group (Bev) and the group with bevacizumab and cilengitide combination 
therapy (Bev+Cile), with 486 upregulated genes and 461 downregulated genes. (B) (C) 
Caveolin 3 (CAV3) and c-src tyrosine kinase (CSK) were significantly decreased by 
combination therapy compared to monotherapy (*p < 0.05) (mean ± SE, n = 3). RQ, 
relative quantification. 
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Supplementary Figure 1 
Microstructure of perivascular space in the center area of U87ΔEGFR rat brain 
tumor   
(A) The fuzzy basal lamina and loose ECM were observed at perivascular space in the 
center area of an untreated U87ΔEGFR tumor. (B) Numerous collagen fibers were 
increased at perivascular space in the center area of a bevacizumab-treated U87ΔEGFR 
tumor. (C) Cluttered and dense ECM around endotherial cells following combination 
therapy was observed. Bar: 500 nm.   
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Tables 
Table 1 
0.5-fold downregulated genes (n = 461) 
Pathway Name Z score P-value Entrez Gene ID Gene Symbol Gene Name 
Integrin-Mediated Cell Adhesion 3.753 0.00398 6654 SOS1 
son of sevenless homolog 1 
(Drosophila) 
 
3.753 0.00398 859 CAV3 caveolin 3 
 
3.753 0.00398 1445 CSK c-src tyrosine kinase 
 
3.753 0.00398 5747 PTK2 PTK2 protein tyrosine kinase 2 
 
3.753 0.00398 53358 SHC3 
SHC (Src homology 2 domain 
containing) transforming protein 3 
 
3.753 0.00398 1793 DOCK1 dedicator of cytokinesis 1 
Signaling of Hepatocyte Growth 
Factor Receptor 
3.604 0.015347 6654 SOS1 
son of sevenless homolog 1 
(Drosophila) 
 
3.604 0.015347 5747 PTK2 PTK2 protein tyrosine kinase 2 
 
3.604 0.015347 1793 DOCK1 dedicator of cytokinesis 1 
GPCRs, Class C Metabotropic 
Glutamate, Pheromone 
3.725 0.026514 55507 GPRC5D 
G protein-coupled receptor, family C, 
group 5, member D 
 
3.725 0.026514 846 CASR calcium-sensing receptor 
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Table 2 
2.0-fold upregulated genes (n = 486) 
Pathway Name Z score P-value Entrez Gene ID Gene Symbol Gene Name 
Inflammatory Response Pathway 3.473 0.017558 3913 LAMB2 laminin, beta 2 (laminin S) 
 
3.473 0.017558 3560 IL2RB interleukin 2 receptor, beta 
 
3.473 0.017558 958 CD40 
CD40 molecule, TNF receptor 
superfamily member 5 
Serotonin Receptor 2 and 
ELK-SRF-GATA4 Signaling 
3.375 0.034361 5604 MAP2K1 mitogen-activated protein kinase kinase 1 
 
3.375 0.034361 2776 GNAQ 
guanine nucleotide binding protein (G 
protein), q polypeptide 
Serotonin Receptor 4-6-7 and 
NR3C Signaling 
3.121 0.041792 5604 MAP2K1 mitogen-activated protein kinase kinase 1 
 
3.121 0.041792 673 BRAF 
v-raf murine sarcoma viral oncogene 
homolog B1 
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